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Objective: Surgical resection is the standard of care for patients with stage I non–small cell lung cancer. For high-
risk patients, however, stereotactic radiosurgery may offer an alternative. We report our initial experience with
stereotactic radiosurgery for treatment of stage I non–small cell lung cancer by a team of thoracic surgeons
and radiation oncologists.
Methods: Patients medically ineligible for operation were offered stereotactic radiosurgery. Thoracic surgeons
evaluated all patients, placed fiducials, and performed treatment planning in collaboration with radiation oncol-
ogists. Median dose of 20 Gy to 80% isodose line was administered as single fraction (range 20–60 Gy,1–3 frac-
tions). Initial response rate, progression, and survival were monitored.
Results: Twenty-one patients underwent stereotactic radiosurgery in 3 years. Fiducial placement resulted in
pneumothorax requiring a pigtail catheter in 10 of 21 patients (47%). Disease showed initial response in 12 of
21 patients (57%), was stable in 5 (24%), progressed in 3 (14%), and was not evaluable in 1 (5%). Proce-
dure-related mortality was zero. With mean 24-month follow-up, estimated 1-year survival probability was
81% (68% confidence interval 0.73–0.90). Median survival was 26.4 months (confidence interval 19.6
months–not reached). Local progression occurred in 9 patients (42%). Median time to local progression was
12.3 months (confidence interval 12 months–not reached).
Conclusion: Preliminary experience indicates that stereotactic radiosurgery (median dose 20 Gy) is safe in this
high-risk group; however, it was associated with significant local progression. Further prospective studies with
multiple fractions are needed to evaluate its efficacy in this population.
Pennathur et al General Thoracic SurgeryLung cancer is the most common cause of cancer-related
mortality in the United States. Surgical resection is the stan-
dard treatment for stage I non–small cell lung cancer
(NSCLC).1-3 With an aging population, many patients
with otherwise resectable lung cancer have other comorbid-
ities, which may preclude surgical resection.4 For these pa-
tients, conventional external beam radiotherapy is typically
offered as treatment, with reported 5-year survivals of
10% to 30%.5-8 These results of conventional external
beam radiation have not been satisfactory, prompting inves-
tigators to study other modalities of treatment for this high-
risk group of patients with lung cancer.
Higher doses of radiation increase local control and can-
cer-specific survival.6 Increasing the dose with conventional
radiation therapy techniques also increases the dose to nor-
mal tissue, however, resulting in increased toxicity. Stereo-
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doi:10.1016/j.jtcvs.2008.06.046The Journal of Thoracic and Ctactic radiosurgery (SRS), a term coined by Leksell, is an
approach that combines multiple convergent beams, precise
localization with a stereotactic coordinate system, rigid im-
mobilization, and single-fraction treatment.9 SRS is well es-
tablished for the treatment of intracranial malignancies, and
its use in extracranial malignancies is now being explored. In
1994, Lax and colleagues10 from the Karolinska Institute de-
scribed a technique of extracranial SRS with a custom-made
body cast and stereotactic coordinates.10 There have been
few reports from the United States of application of SRS
to the treatment of lung malignancies This modality of treat-
ment is evolving.11-15 We have previously reported on our
experience with SRS in patients with primary and metastatic
lung neoplasms.15 In this article, we present our preliminary
results with the use of SRS for the treatment of stage I
NSCLC in medically inoperable patients.
MATERIALS AND METHODS
We reviewed retrospectively our experience at the University of Pitts-
burgh during a 3-year period from 2002 to 2005 with SRS for the treatment
of stage I NSCLC in patients who cold not undergo surgery. Informed con-
sent was obtained from all patients, and the study was approved by the in-
stitutional review board at the University of Pittsburgh.
Selection of Patients
Patients with NSCLC routinely underwent staging with chest computed
tomographic (CT) scan (21/21, 100%). Most patients (18/21, 86%) also un-
derwent a positron emission tomographic (PET) scan. The patient character-
istics are summarized in Table 1. Patients with mediastinal lymph nodes
longer than 1 cm in short axis or a positive PET scan underwentardiovascular Surgery c Volume 137, Number 3 597
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SAbbreviations and Acronyms
CT ¼ computed tomographic
FEV1 ¼ forced expiratory volume in 1 second
NSCLC ¼ non–small cell lung cancer
PET ¼ positron emission tomographic
RECIST ¼ Response Evaluation Criteria in Solid
Tumors
SRS ¼ stereotactic radiosurgery
mediastinoscopy. Mediastinoscopy was performed in 2 patients. The inclu-
sion criteria for SRS in the treatment of patients with stage I NSCLC were as
follows: (1) patients who were considered to have medically inoperable dis-
ease because of poor pulmonary function (predicted postoperative forced
expiratory volume in 1 second [FEV1] less than 40% or diffusion capacity
of the lung for carbon monoxide of less than 40%), high cardiac risk, or
other associated comorbidities, or (2) patient refusal for surgery. In this
series, all patients had medically inoperable disease. All patients were eval-
uated by a thoracic surgeon and a radiation oncologist before treatment.
Treatment was delivered with the CyberKnife (Accuray, Sunnyvale, Calif)
system, a frameless system that consists of a 6-MV linear accelerator
mounted on a computer-controlled robotic arm. The technology and the
protocol used with this system have previously been described in detail.11,15
Treatment Protocol
A total of 1 to 4 fiducials, which are small tumor markers, were placed
percutaneously with CT guidance by thoracic surgeons in and around the
tumor for tumor tracking. An immobilization device (Alpha Cradle; Smith-
ers Medical Products, North Canton, Ohio), which partially immobilizes the
patient to decrease the motion and provide a reproducible setup, was custom
made for each patient. A week to 10 days after placement of fiducials, a con-
trast-enhanced CT scan of the chest and upper abdomen was performed. The
thoracic surgeon and radiation oncologist then evaluated the CT scan and
jointly formulated a treatment plan. We made treatment volume consider-
ations to avoid radiation injury in the surrounding normal lung, spinal
cord, heart, aorta, liver, and stomach. We used the treatment planning soft-
ware to outline the gross tumor volume. In addition, we sought to add a 5- to
10-mm radial margin to the treated volume, although this goal was limited
by the opposing goal of avoiding toxicity to adjacent critical structures. On
the day of the treatment, the patient was repositioned accurately to simulate
the original planning setup. Tumor motion resulting from patient respiration
was minimized by two techniques. A breath-holding method was used in 16
patients, whereas a dynamic tumor-tracking system (Synchrony; Accuray)
was used in the remaining 5 patients. Targeting was coupled with a real-
time image-guidance system. Patients were treated with 20 Gy prescribed
to the 80% isodose line (1–3 fractions, total dose 20–60 Gy). The biologi-
cally effective dose of 20 Gy, determined by the linear quadratic equation, is
estimated to be equivalent to about 60 to 70 Gy. Early in our experience, we
used a 20-Gy dose; as we gained more experience, we increased this to a total
of 60 Gy for peripheral lesions. This change was made with caution because
of the reported toxicity associated with an increased dose. A dose of 20 Gy
in a single fraction was administered in 17 patients; the last 4 patients with
peripheral lesions were treated with a total dose of 60 Gy in three fractions.
Follow-up of Patients and Assessment of Response
Patients were followed up at 3-month intervals with clinical examina-
tions, CT scans, and PET scans. Modified Response Evaluation Criteria
in Solid Tumors (RECIST) criteria, incorporating not only lesion size but
also the quality of the lesion and metabolic uptake on PET scan, were
used to assess response to treatment at 3 months15-17 (Table 2). Patients598 The Journal of Thoracic and Cardiovascular Surwere evaluated for initial response rate, time to progression, and overall
survival.
Data Collection and Statistical Analysis
The objective of the study was to determine the outcomes of SRS in
the treatment of stage I NSCLC. Information on patient demographic char-
acteristics, tumor characteristics, treatment, and comorbidities (Charlson
comorbidity index) was collected.18 Specific end points studied were com-
plications, clinical response rates, time to progression, and overall
survival. The pretreatment CT scan was used as a baseline for evaluation
of response and disease progression. Local disease progression of the treated
lesion was assessed in accordance with the modified RECIST criteria relative
to baseline diameter. The time to progression was calculated from the treat-
ment date after censoring data from patients who died without progression.
Kaplan–Meier plots were constructed with 68% Greenwood confidence
limits. Association between categoric variables was tested with the Fisher ex-
act test or the c2 test.
RESULTS
A total of 21 patients underwent SRS during a 3-year
period. There were 9 men and 12 women, with a median
age of 71 years (range, 61–85 years). The most common rea-
son for SRS was poor pulmonary function test results preclud-
ing curative resection (14/21, 67%). In this group of patients
with poor pulmonary function, the median FEV1 was 0. 66 L
(range, 0.5–0.86 L), median FEV1 was 25% (range, 15%–
46%), and median lung diffusion capacity for carbon
dioxide was 30.5% of predicted (range, 19%–58%). Several
patients had multiple comorbidities, and the mean Charlson
comorbidity index was 5.2 (median 5, range 0–10). There
were 14 patients with stage IA NSCLC and 7 with stage IB.
The mean size of the lesion was 2.2 cm (range, 0.9–5.5 cm).
The patient characteristics are summarized in Table 1.
TABLE 1. Patient characteristics
Total patients (No.) 21
Sex (male/female) 9:12
Age (y)
Median 71
Range 61–85
Stage (No.)
IA 14
IB 7
Staging procedures* (No.)
Computed tomographic scan 21
Positron emission tomographic scan 18
Mediastinoscopy 2
Histologic type (No.)
Squamous 8
Adenocarcinoma 6
Non–small cell lung cancer (unspecified) 6
Not determined 1
Reason for stereotactic radiosurgeryy (No.)
Poor pulmonary function test results 14
Increased cardiac risk 6
Multiple comorbidities 8
*Most patients underwent multiple staging procedures. ySome patients had multiple
reasons for stereotactic radiosurgery.gery c March 2009
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Response CT mass size CT mass quality PET*
Complete (meet any 2 criteria) Lesion disappearance (scar) or
<25% original size
Cyst cavity formation; low density SUV<2.5
Partial (meet any 1 criterion) Decrease>30% in sum of LDs of
target lesions
Mass central necrosis or central
cavity with liquid density
Decreased SUV or FDG uptake
area
Stable lesion (meet any 1
criterion)
Decrease<30% in sum of LDs of
target lesions
Mass solid appearance, no central
necrosis or cavity
Unchanged SUV or FDG uptake
area
Progression (meet any 2 criteria) Increase>20% in sum of LDs of
target lesions
Solid mass, invasion of adjacent
structures
Higher SUV or larger FDG uptake
area
CT, Computed tomographic; PET, positron emission tomography; SUV, standardized uptake value (of fluorodeoxyglucose F 18); LD, lesion diameter; FDG, fluorodeoxyglucose F
18. *Positron emission tomography was performed selectively.G
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After percutaneous fiducial placement, 10 patients (10/21,
47%) had pneumothorax that necessitated placement of
a pigtail catheter. The median hospital stay after placement
of fiducials was 1 day (range 0–17 days). One patient was ad-
mitted with exacerbation of chronic obstructive pulmonary
disease after SRS. There were no procedure-related deaths.
Initial Response
Response was assessed at 3 months according to the mod-
ified RECIST criteria, as described previously15-18 (Table 2).
Response could not be evaluated in 1 patient because of
early death from pneumonia at 3.6 months. In the remaining
patients, an initial complete response was observed in
7 patients (7/20, 35%), partial response was observed in 5
(5/20, 25%), stable disease was observed in 5 (5/20,
25%), and progression occurred in 3 patients (3/20, 15%).
Survival
There were no procedure-related deaths. There were 10
deaths during the follow-up period. The mean follow-up
of the remaining patients was 24 months (median 21 months,
range 12–43 months). The probability of overall survival at
1 year was estimated to be 81% (68% confidence interval
73%–90%). The median survival was 26.4 months (68%
confidence interval 19.6 months–not reached; Figure 1).
During follow-up, local progression occurred in 9 patients
(42%, 68% confidence interval 32%–54%), and the
median time to local progression was 12.3 months (68%
confidence interval 12 months–not reached).
DISCUSSION
Surgery is the treatment of choice for stage I NSCLC and
offers the best chance for cure.1-3 For patients with lung
cancer who cannot be operated on for medical reasons, there
are few effective curative options. The primary standard
treatment for medically inoperable stage I NSCLC is
conventional external beam radiation therapy alone. Many
patients who cannot undergo operation are elderly, with
multiple comorbidities, and are typically not treated with
chemotherapy.19 Sibley and colleagues6 reported the resultsThe Journal of Thoracic andof radiation therapy in 141 patients with stage I NSCLC. The
median survival was 18 months, and the estimated overall
survival at 2 and 5 years was 39% and 13%, respectively.
Local failure alone represented the most common mode
of failure (42%). Krol and colleagues7 reported the results
in 108 patients with medically inoperable stage I NSCLC.
The overall survival was estimated to be 75%, 31%, and
15% at 1, 3, and 5 years, respectively. Local progres-
sion occurred in 71 patients (65.7%). Finally, Qiao and
colleagues,8 in a meta-analysis of the results of radiation
therapy for stage I NSCLC, reported estimated overall
3- and 5-year survival of 34% and 21%, respectively.8
Because the results of conventional external beam radiation
are suboptimal, novel treatment approaches such as SRS and
radiofrequency ablation (RFA) may be applicable in this
high-risk group of patients.11-17 The results of SRS for the
treatment of stage I NSCLC in our study compare favorably
with the previously mentioned studies in which conven-
tional radiotherapy was used.
FIGURE 1. Kaplan–Meier plot illustrating overall survival for entire
group. Time shown on x-axis is in months from stereotactic radiosurgery
(SRS). Error bars indicate 68% confidence intervals for probability of over-
all survival.Cardiovascular Surgery c Volume 137, Number 3 599
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therapies such as SRS and radiofrequency ablation (RFA),
because many treated patients have residual scarring. We
therefore used modified RECIST criteria that incorporated
not only lesion size but also lesion quality and assessment
of metabolic activity by PET scanning to evaluate re-
sponse.15-17 There is, however, no consensus in the literature
with regard to the determination of initial response, and ul-
timately recurrence and survival are the end points that
need to be evaluated to assess the efficacy of treatment
with such ablative therapies as SRS.
In this article, we report our initial experience in patients
with stage I NSCLC treated with SRS using a frameless ste-
reotactic system. Whyte and colleagues11 provided the first
report from the United States with a similar system for
frameless SRS in 23 patients treated with a single fraction
of 15 Gy. SRS has also been reported in several other parts
of the world, including Japan, where an early study was per-
formed by Uematsu and associates.20-25 Timmerman and
coworkers12 reported results for 37 patients with stage I
NSCLC treated with SRS. In that dose escalation study,
the dose was escalated from 24 Gy to 60 Gy in three frac-
tions. At a median follow-up of 15 months, 6 patients had
local failure; all had received less than 18 Gy per fraction.
Local progression occurred between 3 and 18 months (me-
dian 13 months) after treatment. The disease-free and overall
survivals at median follow-up of 15 months were 50% and
64%, respectively.
The biologically effective dose is estimated to be much
higher with SRS than with standard external beam radiation.
Biologically effective dose and local control have been
reported on by Onishi and colleagues.22 Onishi and col-
leagues22 evaluated clinical outcomes of 245 patients with
stage I NSCLC from 13 Japanese institutions and reported
a lower local recurrence rate when the biologically effective
dose of more than 100 Gy was used. In our study, the estimated
median biologically effective dose was about 60 to 70 Gy, and
a significant incidence of local progression was noted. In addi-
tion to the dose, other factors that may contribute to local pro-
gression include the margins obtained around the tumor and
the technique of tumor tracking during respiration.
Dose Escalation: Local Control and Toxicity
Increase in the dose improves local control; however, it
may also be associated with increased toxicity, particularly
when treating central lesions. Timmerman and colleagues13
recently reported their results with SRS (60–66 Gy in three
fractions) in a phase II study of 70 patients with medically
inoperable stage I NSCLC. At a median follow-up of 17.5
months, Timmerman and colleagues13 reported good local
control of 95% and a 2-year overall survival of 54%. There
was excessive toxicity noted in central tumors, however,
with a 2-year freedom from severe toxicity of 54% in central
lesions versus 83% in peripheral lesions. Of the 28 deaths600 The Journal of Thoracic and Cardiovascular Surduring follow-up, 6 (8.6%, 6/70) were treatment related.
This increase in procedure-related mortality and the increase
in toxicity, particularly with central lesions, led Timmerman
and colleagues13 to conclude that this regimen should not be
used for patients with tumors near central airways.
Le and colleagues14 reported the results of a dose escala-
tion study in patients with lung neoplasm with single-frac-
tion treatment. There were 21 patients with stage I NSCLC
and 11 with metastatic tumors. The doses administered
were less than 20 Gy in 10 patients, 25 Gy in 20, and 30
Gy in 2. At a median follow-up of 18 months, Le and col-
leagues14 reported a 1-year survival of 85% for patients
with stage I NSCLC. The 1-year freedom from local pro-
gression was 91% for patients who received a dose greater
than 20 Gy, versus 54% for those who received less than
20 Gy. Late toxicity was observed in 8 patients, however,
all of whom had received more than 20 Gy. There were 3
deaths related to the procedure, for a treatment related mor-
tality of 9.7%. All the patients who died had received more
than 25 Gy in a single fraction and had centrally located le-
sions. In addition, all these patients had received chemother-
apy, and 2 of the 3 had received previous radiation. Some of
these patients had received gemcitabine, which is associated
with radiation-recall toxicity. These studies show that
although local control with SRS may be very good with
higher doses, caution must be exercised in selecting the
dose schema, particularly for patients with central lesions.
In our study, in which a lower dose was used, no treatment-
related deaths were observed. It is important, however, to note
that some toxicity may occur late, and further follow-up is re-
quired to determine any late toxicity. Our current approach is
to treat only peripheral lesions with a higher dose of 60 Gy in 3
fractions to balance the toxic effects with local control. Fur-
ther, as highlighted by Le and colleagues,14 caution should
be exercised, particularly with gemcitabine-based adjuvant
therapy, when a large single fraction dose is used.
There are several radiosurgical treatment devices, and di-
rect comparisons of results between these devices are not
available. Some systems use the breath-holding technique
and do not require placement of fiducials.12 Patients treated
with such systems still require a CT-guided or broncho-
scopic biopsy of the lesion, however, which may be compli-
cated by pneumothorax. Other systems use a dynamic
tracking system. In our center, we used the CyberKnife,
which at present requires the placement of fiducials to help
track tumor motion during respiration. One of the disadvan-
tages of transthoracic placement of fiducials under CT guid-
ance is the development of pneumothorax, particularly in
these patients with medically inoperable disease because
of pulmonary dysfunction. For these high-risk patients, we
had a low threshold for placement of pigtail catheters to
drain the pneumothorax. Recent advances in electromag-
netic navigation–guided bronchoscopy and placement of fi-
ducials may decrease the incidence of pneumothorax.26gery c March 2009
Pennathur et al General Thoracic Surgery
G
T
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geons were actively involved in patient selection, placement of
fiducials, contouring the lesion, and treatment planning in close
collaboration with radiation oncologists. The thoracic surgeons’
expertise with regard to the anatomy, the physiologic assess-
ment of the patient, and the ability to make an evaluation of
the surgical risk was valuable in the selection of patients for
SRS. It is particularly important that the determination of med-
ical inoperability be made by the thoracic surgeon. One factor
alone, such as poor pulmonary function test results, may not
make a patient ineligible for operation. An interesting study
demonstrated excellent survival after surgical resection in
a highly selected group of patients with early-stage NSCLC
and poor pulmonary function test results (mean FEV1 0.7,
29% of predicted).27 In that study, after surgical resection
with or without associated lung volume reduction surgery, the
overall survival at 5 years was 68%. The study emphasizes
that one factor alone does not make a patient inoperable, and
this decision regarding operability should be made by the
thoracic surgeon after a comprehensive evaluation of the patient
that includes not only pulmonary function tests but also other
patient-specific factors and comorbidities.
The results of SRS in our study appear to be equivalent or
superior to the reported results of conventional radiother-
apy.5-8 Further prospective studies are required, however,
for definitive comparison of SRS with conventional external
beam radiation treatment or other emerging technologies
such as RFA. Our study has the limitations inherent to retro-
spective studies, such as selection bias. In addition, longer
follow-up for this cohort is needed, and full evaluation of sur-
vival end points will require greater maturity of time-to-event
data. In this preliminary study, we used a median dose of 20
Gy in a single fraction in most cases, and minimal toxicity
was observed. A significant incidence of local progression
was noted. We now have an ongoing, prospective, institu-
tional review board–approved study to evaluate the efficacy
of a regimen with 60 Gy in three fractions for lesions that are
not central in location in medically inoperable patients.
CONCLUSIONS
In summary, this study is a preliminary report on the use
of SRS for the treatment of medically inoperable stage I
NSCLC, and our results appear to be equivalent or superior
to the results of conventional radiation therapy. Several
factors merit further investigation, including optimal patient
selection, appropriate dose, fractionation, and balancing the
efficacy of the treatment against toxicity. In addition, the
role of adjuvant therapy along with SRS remains to be deter-
mined. Surgical resection remains the standard treatment for
stage I NSCLC in operable cases1-3; however, SRS may have
a role for patients with medically inoperable disease. Pro-
spective studies are currently in progress at our institution
and others to address these issues and to define the role of
SRS in the treatment of lung neoplasm. Thoracic surgeonsThe Journal of Thoracic and Cshould continue actively to investigate new technologies
such as SRS and to add these techniques to their armamentar-
ium in the treatment of lung neoplasm. In conclusion, SRS
may provide an alternative option for high-risk patients
with stage I NSCLC who are not medically fit for surgery.
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Discussion
Dr Jack A. Roth (Houston, Texas). Recent advances with 3-di-
mensional conformal techniques can compensate for lung motion,
and they can allow delivery of very high single fractions to primary
lung tumors in patients with clinical stage I lung cancer. The mem-
bers of the Pittsburgh group are innovators in applying novel technol-
ogies to the treatment of thoracic cancers, and now they demonstrate
the application of this technology to the treatment of lung cancer in
patients with medically inoperable disease. Importantly, thoracic sur-
geons evaluated all patients and performed treatment planning in col-
laboration with radiation oncologists. As these novel technologies
evolve, it is going to be critical for thoracic surgeons to continue to
participate in the delivery of SRS and other new therapies.
There have been several series of patients with clinical stage I
lung cancer treated with stereotactic radiation in the United States
and Japan, and these include both medically inoperable and surgi-
cally resectable disease. Both the local control rates and the 5-year
survivals in those studies appear to be comparable to those reported
in surgical series. These studies administered considerably higher
doses of radiation than used in this study, which could explain
the high local failure rate that Pennathur and colleagues observed.
There are planned or completed phase II clinical trials, both in
the United States under the Radiation Therapy Oncology Group
and in Japan under the Japan Clinical Oncology Group, to evaluate
SRS for the treatment of resectable stage I NSCLC. If these results
are confirmed, this type of technology could be competitive with
surgery for operable stage I disease, and I think that it is therefore
imperative that we begin to consider the design of randomized clin-
ical trials to eventually assess the benefit of SRS.
I have several questions. Dr Pennathur, one fraction of 20 Gy,
which has a biologic effective dose calculated by our radiation on-
cologists as 60 Gy, is less than the conventional dose of 66 Gy in 33
fractions that’s usually given to these patients. This could explain
the high local recurrence rate. Why was such a low dose given,
and are there plans to increase both the dose and the margins be-
yond those that you reported in your study?
Second, the patients had multiple comorbidities. Could you es-
timate the lung cancer–specific survival for your cohort of patients?
Finally, do the radiation oncologists at your institution plan to
offer this technology at higher doses to patients with potentially op-
erable disease?602 The Journal of Thoracic and Cardiovascular SuDr Pennathur. Thank you, Dr Roth, for your comments and ques-
tions. I’m going to take the third question first. No, our radiation on-
cologists are not going to offer SRS to patients with operable stage I
NSCLC. We believe that the data is in evolution and although the data
from Japan is interesting, do not yet support that. I will discuss further
about this after addressing the first two questions.
In answer to your first question, yes, I think that the local recur-
rence rate in our series has been high. It’s about 40% of local pro-
gression. I think several factors may have played a role in this. As
you rightly pointed out, I think dose is the number one factor. A 20-
Gy dose has been estimated to be equivalent to anywhere between
60 Gy and 70 Gy and is estimated by the linear quadratic equation,
which makes a lot of assumptions, so that the radiation oncologist
who actually calculates it comes with a specific number. Everybody
agrees that this is not very precise, but our estimate is that it’s some-
where around 70 Gy or so. The second issue is that with higher
doses, the three-fraction schema of 20 Gy times 3, a 60 Gy dose,
is supposed to be equal to a biologic effective dose of 180 Gy.
Now, Timmerman and colleagues13 have shown that with central
lesions, this regimen has been highly toxic. The mortality from us-
ing this regimen has been close to 10%, which is somewhat alarm-
ing, but most of these patients who died had central tumors. Of the 6
deaths they had, 4 were of patients with central tumor. In our series
of 21 patients, 11 had central tumors and 10 had peripheral tumors.
Early on, when we started out using SRS, we used the lower dose.
The first reason for this was caution. The second reason was that the
pulmonary function test results in these patients were quite poor,
and the radiation oncologists had some concerns about giving
a high dose. I must add that during the last year and a half, we
have gone up to three fractions of 20 Gy for peripheral lesions.
In this series, 4 patients received a total of 60 Gy for peripheral le-
sions, but the follow-up is not long enough as for the original 20
patients, and almost all the recurrences were in the first 20-Gy
group, so the local progression rate is significant.
In terms of the margins, yes, we shoot for a margin of at least 5
mm, but we presented data about a year ago suggesting that if the
margins were less than 1 cm in wedge resections, our recurrence
rates were much higher. So we want to go for about a 1 cm margin,
but this is limited by the critical structures around the lesion and by
the radiation exposure that these critical structures sustain. Unfor-
tunately, many times it’s not 1 cm. It’s closer to 5 mm.
Finally, I think the issue about recurrence is the technique. Early
on, we used the breath-hold technique. Now we are using more dy-
namic tracking wherein the patient’s breathing is dynamically
tracked by the camera and then the radiation is delivered in sync
with the patient’s breathing. In this series, again, only 5 patients
were treated that way. The rest were treated with the breath-hold
technique. I think that all this may explain the increase in terms
of local progression. Finally, I think the issue is that our aggressive
follow-up and imaging also contributed to early detection of recur-
rence.
Now, the second question was related to the dose, Dr Roth?
Dr Roth. Yes.
Dr Pennathur. With respect to the dose, again, we have gone up
to 60 Gy for peripheral lesions. For central lesions, we are looking
at one of the Japanese regimens, which is 12 Gy times 4, for
a 48-Gy dose, which gives a biologically effective dose of more
than 100 Gy.rgery c March 2009
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operable cases, I think that the Japanese literature is quite encourag-
ing. Unfortunately, I think that there is a disconnect between the sur-
vival figures quoted in the Japanese literature and the survival
figures quoted in the United States. I think, for example, some of
the Japanese surgical series have had approximately 90% to 100%
5-year survivals, with survivals in the 80% range quoted after
SRS I think in the United States we have not seen survivals in the
90% range for stage I lung cancer at 5 years. I wonder whether there
is some biologic difference in terms of the patients we are treating,
perhaps in the basic substrate of the patients themselves. I think it
would be reasonable for patients with medically inoperable disease
to compare the CyberKnife with some other therapy for medically
inoperable cases. With respect to SRS for surgically operable cases,
I think that we may need more data in the United States to pursue
this. Certainly, as you mentioned, this is a hotly investigated area,
with a lot of interest from a lot of groups, including ours, and we
are looking at this very closely. Thank you for your comments
and excellent questions.
Dr Tomasz Grodzki (Szczecin, Poland). I congratulate you on
your excellent presentation; however, I am still doubtful whether
those patients really had inoperable disease, because if you evalu-
ated them, you probably performed mediastinoscopy. This means
that they survived anesthesia. If you placed those metal markers,
it means that they were subjected to pneumothorax, and they all sur-
vived it. This was a kind of functional test for segmentectomy. I
think I would prefer to perform segmentectomy and then radiation.
What was the N status of those patients? You didn’t mention it.
Was this clinical stage I or pathologic stage I?
Dr Pennathur. These patients, if they had enlarged lymph nodes
and positive PET scan results in the mediastinum, underwent a me-
diastinoscopy and N2 disease was ruled out. Otherwise, they did
not undergo any other invasive staging, such as video-assisted thor-
acoscopic surgical staging, for example. Two patients underwent
mediastinoscopy, and they certainly did not have any invasive pro-
cedures before SRS. So this is primarily clinical staging, with inva-
sive staging in selected patients, to rule out N2 disease. The issue of
medical inoperability is a critical one, and I think that it is important
that surgeons be involved, because what is medically inoperable for
a thoracic surgeon is not the same as what is medically inoperable
for a pulmonologist and is different still for a radiation oncologist.
These patients had a low FEV1 of 0.6 and had multiple comorbid-
ities. The median Charlson Comorbidity Index value was 5.5, and
we have validated data suggesting that the incidence of postopera-
tive complications is significantly higher on multivariate analysis
once this score reaches 3 to 4. So I do think that this was a high-
risk group of patients. I think, however, that your point is excellent.
There may be patients with predominant upper lobe emphysema
and lung cancer there with low FEV1 who would certainly benefit
from lung resection along with lung volume reduction. I therefore
think that it’s critical for thoracic surgeons to evaluate these patients
before declaring the disease inoperable, and these patients were all
very carefully assessed before they were subjected to SRS.
Dr Jessica S. Donington (Stanford, California). I congratulate
you on this work. At Stanford we also feel that it’s important for
surgeons to embrace this kind of technology. We are really the ex-
perts on the treatment of early-stage lung cancer, and we need to
know all the options that are available for our patients.The Journal of Thoracic and CI have two questions. One has to do with the local recurrences. In
our work, we’ve noticed a difference in local recurrences between
T1 and T2 tumors. The ability to give the full isodose for those
smaller tumors is much easier. Did you note this? Also, one of
the significant differences we find between surgery and radiother-
apy is clearly the treatment of the lymph nodes, and we did have
more nodal recurrences than we would like. That was an area where
there were a lot of recurrences. Can you comment on the difference
between your local recurrences, nodal recurrences, and distant re-
currences in these patients?
Dr Pennathur. We didn’t really find a difference in terms of lo-
cal progression-free survival between T1 and T2 tumors. Nine pa-
tients had local progression. In many instances, this is associated
with regional and also distant disease, but it was counted as local
progression. Local-only progression occurred in fewer than 5 pa-
tients. Sometimes people might report it that way, but for this study
we decided that any local recurrences need to be considered. Thank
you for your comments and questions.
Dr Mark Block (Hollywood, Florida). I enjoyed your presenta-
tion, and I congratulate your group on really providing objective lead-
ership in studying the ablative therapies for these early lung cancers.
I have two questions. First, how do you deal with lesions that are
close to important structures, like hilar lesions close to the pulmo-
nary artery or the aorta, a lingular lesion that’s next to a left ventric-
ular free wall? You don’t want to give them 70 Gy radiation.
Second, are you at all familiar with the new fiducial-free systems
that are being marketed? The reason I have concerns about that is
that in our local market, the person who owns the CyberKnife facil-
ity–because it’s an independent facility–was boasting to me the
other day about how they’re going to get a fiducial-free system
and then be able to take the patient right from the screening CT
scanner to the CyberKnife to zap those little 5-mm lesions without
ever having to worry about a biopsy. This leads me to the last point,
which is that I think the use of this technology is unfortunately go-
ing to be driven more by marketing and promotion than by science.
I think your group is in a unique position to provide the most objec-
tive data on evaluating this technology. Most of the other literature
out there has been written by people with a financial interest in in-
creasing SRS use. I therefore challenge you to think about ways in
which you can influence the debate by more than simply presenting
your objective data. There must be policy discussions about how
we’re going to manage these patients.
Dr Pennathur. Thank you, Dr Block. Those are really excellent
thoughts. In terms of the fiducial-free system, we have heard about
it and we have discussed it with the radiation oncologists and with
the physicists. At this point, we are not going to get into it, because
we don’t have the data to prove that this fiducial less system is as
accurate in tracking the tumor as the one we currently use with
fiducials. Some tumors move about a good 2 or 3 cm with breath-
ing, and whether the fiducial-free system is going to be tracking
this, we really do not know. The issue in terms of the study of these
newer technologies is that I think that thoracic surgeons should take
a lead. We have been taking care of this for a long time, and we also
look at things a little bit differently and more objectively in terms of
recurrence and survival and so forth. I think that it will be critical for
us to get involved with these newer technologies, and we are trying
to evaluate every aspect critically and to identify patients who
would benefit versus patients who might not benefit.ardiovascular Surgery c Volume 137, Number 3 603
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to tolerate a 20-Gy dose, which equals a 70-Gy dose. The moment
you go up to a higher dose, however, you add risk. I think in the
Stanford series, a 25-Gy dose in a central location was associated
with about 2 deaths, for single-fraction radiation. A 20-Gy dose,
however, may be somewhat safer. The Japanese have proposed
a newer schema, which is a total of 48 Gy, with each fraction
only about 12 Gy for central lesions. I think we do have to be a little
careful about the central lesions and what kind of dose we need to
use, and I think we need to follow, evaluate them, and study them
more carefully.
Dr Todd L. Demmy (Buffalo, New York). I have two quick
questions. Your group is also reporting on RFA for similar pa-
tients. How are you sorting out SRS technology versus the
competing technology of RFA? By extension, we’re finding pa-
tients with RFA sometimes don’t have recurrence at the target
lesion but at a location nearby, which points to a problem with
this technology. You can only target what you can see on the
initial CT scan, not the minimal residual disease that you can’t
image and that is presumably cleared better by lobectomy or
segmentectomy. When you report your results, are you going
differentiate the recurrences at the initial target area from604 The Journal of Thoracic and Cardiovascular Surlesions that recurred nearby in the downstream path of the tu-
mor spread?
Dr Pennathur. Thanks for your comments, Dr Demmy. In terms
of the RFA and CyberKnife, I think they can potentially be comple-
mentary. We absolutely don’t use RFA for central lesions. We had 1
patient who underwent RFA and brachytherapy who had a fatal he-
moptysis about 3 weeks after the procedure, and we do not know
whether it was the brachytherapy or RFA which caused it, but we
haven’t used RFA since for any central lesions. We use a modified
dose schema for the central lesions. In terms of peripheral lesions,
they can be complementary. For example, if there is a recurrence af-
ter RFA, one could use SRS, and vice versa. And sometimes for a pe-
ripheral lesion, it is the choice of the physician as to the technology
to use. I think the other point which you brought up, which is that we
treat the small lesion which we see but we don’t look into micro-
scopic spread, is critical. I think the issue about margins becomes
very important, and we believe that we need to have at least a 1-cm
margin. We evaluate our recurrences in the lobe as well as the
progressed lesion, and I think the upcoming American College of
Surgeons Oncology Group (ACOSOG) trial on RFA also is going
to be reporting the same way. We thank the Association for the
privelege of presenting this paper.gery c March 2009
